Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors - PubMed (original) (raw)
Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors
Sean P Cleary et al. J Am Coll Surg. 2004 May.
Abstract
Background: Pancreatic cancer is a rapidly fatal disease with very few 5-year survivors even after aggressive surgical treatment. Our objective was to determine the actual 5-year survival rate of patients with pancreatic adenocarcinoma who underwent a resection with curative intent in 5 teaching hospitals within the University of Toronto system. We then sought to determine clinical and histopathologic features of 5-year survivors to determine factors associated with a favorable prognosis.
Study design: A retrospective chart review was performed using surgeon and hospital databases to identify patients who had a surgical resection for pancreatic adenocarcinoma between January 1, 1988, and December 31, 1996.
Results: One hundred twenty-three patients who had a resection and a pathologic diagnosis of pancreatic adenocarcinoma with complete followup were identified from seven surgical practices. Mean survival (+/- standard error) in this series was 31.7 +/- 3.5 months (median 13.6 months). There were 18 5-year survivors (14.6%), including 5 patients (4.1%) who survived longer than 10 years. The survivors included 13 patients who had undergone a Whipple resection, 4 who had undergone a distal pancreatectomy, and 1 who had undergone a total pancreatectomy. Tumor size, lack of jaundice at presentation, negative nodal disease, low tumor grade, and a low tumor stage were all significant predictors of survival in univariate analysis (all p < 0.05). Only tumor stage (hazard ratio [95% confidence interval]: stage IIA 1.5 [0.8 to 2.8], stage IIB 2.6 [1.4 to 4.7], stage III 1.8 [0.8 to 4.3]) and tumor grade (hazard ratio [95% confidence interval]: moderately differentiated 1.6 [0.9 to 2.9], and poorly differentiated 3.1 [1.6 to 6.2]) were independently associated with survival differences in a multivariate Cox proportional hazards model.
Conclusions: We conclude that longterm survival from pancreatic adenocarcinoma is possible if the disease is identified in its early stages. These and other similar data should provide further stimulus for the development and evaluation of novel screening strategies to improve early detection of this disease.
Similar articles
- Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?
Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, Gullerud RE, Donohue JH, Nagorney DM, Farnell MB. Schnelldorfer T, et al. Ann Surg. 2008 Mar;247(3):456-62. doi: 10.1097/SLA.0b013e3181613142. Ann Surg. 2008. PMID: 18376190 - Pancreatic carcinoma: reappraisal of surgical experiences in one Japanese university hospital.
Yamaguchi K, Shimizu S, Yokohata K, Noshiro H, Chijiiwa K, Tanaka M. Yamaguchi K, et al. Hepatogastroenterology. 1999 Nov-Dec;46(30):3257-62. Hepatogastroenterology. 1999. PMID: 10626197 - En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients.
Yekebas EF, Bogoevski D, Cataldegirmen G, Kunze C, Marx A, Vashist YK, Schurr PG, Liebl L, Thieltges S, Gawad KA, Schneider C, Izbicki JR. Yekebas EF, et al. Ann Surg. 2008 Feb;247(2):300-9. doi: 10.1097/SLA.0b013e31815aab22. Ann Surg. 2008. PMID: 18216537 - Pancreatic carcinoma deemed unresectable at exploration may be resected for cure: an institutional experience.
Chao C, Hoffman JP, Ross EA, Torosian MH, Eisenberg BL. Chao C, et al. Am Surg. 2000 Apr;66(4):378-85; discussion 386. Am Surg. 2000. PMID: 10776876 Review. - Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium.
Miller RC, Iott MJ, Corsini MM. Miller RC, et al. Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):364-8. doi: 10.1016/j.ijrobp.2008.11.069. Int J Radiat Oncol Biol Phys. 2009. PMID: 19735864 Review.
Cited by
- Influence of non-jaundice stage at diagnosis on clinicopathological features and long-term survival of patients with periampullary carcinomas.
Peng X, Jiao X, Zhao P, Zhu R, Sun Y, Zhou L. Peng X, et al. Medicine (Baltimore). 2019 Nov;98(45):e17673. doi: 10.1097/MD.0000000000017673. Medicine (Baltimore). 2019. PMID: 31702620 Free PMC article. - Isoform-specific upregulation of palladin in human and murine pancreas tumors.
Goicoechea SM, Bednarski B, Stack C, Cowan DW, Volmar K, Thorne L, Cukierman E, Rustgi AK, Brentnall T, Hwang RF, McCulloch CA, Yeh JJ, Bentrem DJ, Hochwald SN, Hingorani SR, Kim HJ, Otey CA. Goicoechea SM, et al. PLoS One. 2010 Apr 26;5(4):e10347. doi: 10.1371/journal.pone.0010347. PLoS One. 2010. PMID: 20436683 Free PMC article. - Sonoporation for Augmenting Chemotherapy of Pancreatic Ductal Adenocarcinoma.
Castle J, Kotopoulis S, Forsberg F. Castle J, et al. Methods Mol Biol. 2020;2059:191-205. doi: 10.1007/978-1-4939-9798-5_9. Methods Mol Biol. 2020. PMID: 31435922 Free PMC article. Clinical Trial. - Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia.
Moniaux N, Chakraborty S, Yalniz M, Gonzalez J, Shostrom VK, Standop J, Lele SM, Ouellette M, Pour PM, Sasson AR, Brand RE, Hollingsworth MA, Jain M, Batra SK. Moniaux N, et al. Br J Cancer. 2008 May 6;98(9):1540-7. doi: 10.1038/sj.bjc.6604329. Epub 2008 Apr 8. Br J Cancer. 2008. PMID: 18392050 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical